Purpose Proliferation is a hallmark of cancer. Using a combined genomic approach, FGD5 amplification has been identified as a driver of proliferation in Luminal breast cancer. We aimed to describe FGD5 copy number change in breast cancer, and to assess a possible association with tumour proliferation and prognosis. Methods We used fluorescence in situ hybridization targeting FGD5 and chromosome 3 centromere (CEP3) on formalin-fixed, paraffin-embedded tissue from 430 primary breast cancers and 108 lymph node metastases, from a cohort of Norwegian breast cancer patients. We tested the association between FGD5 copy number status and proliferation (assessed by Ki67 levels and mitotic count) using Pearson's Chi square test, and assessed the prognostic impact of FGD5 copy number change by estimating cumulative risks of death and hazard ratios. Results We identified FGD5 amplification (defined as FGD5/CEP3 ratio C2 or mean FGD5/tumour cell C4) in 9.5% of tumours. Mitotic count and Ki67 levels were higher in tumours with FGD5 copy number increase, compared to tumours with no copy number change. After 10 years of follow-up, cumulative risk of death from breast cancer was higher among cases with FGD5 amplification [48.1% (95% CI 33.8-64.7)], compared to non-amplified cases [27.7% (95% CI 23.4-32.6)]. Conclusions FGD5 is a new prognostic marker in breast cancer, and increased copy number is associated with higher tumour proliferation and poorer long-term prognosis.
Introduction
Sustaining proliferative signalling is a hallmark of cancer [1] , and the proliferation marker Ki67 is included in current treatment guidelines for breast cancer patients [2] . Given the crucial role of proliferation, identification of essential proliferation-associated genes could be important for prognostication and development of targeted treatment.
Using data from two independent datasets [3, 4] , and by combining gene expression and copy number analysis data with data from a genome-wide RNA-mediated interference screen on breast cancer cell lines, Gatza et al. identified eight essential genes (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) uniquely amplified in highly proliferative luminal (non-basal) breast tumours [5] . Amplification of four of these genes (FGD5, METTL6, DTX3 and MRPS23) was associated with poorer prognosis. FGD5 (Faciogenital Dysplasia 5), located on the short arm of chromosome 3(3p25.1) [6] , is a member of the FGD family, and mutations in FGD1 result in Faciogenital Dysplasia [7] . Genetic and epigenetic changes on the short arm of chromosome 3 have been found in epithelial tumours, including breast cancer [8] [9] [10] . FGD5 methylations and deletions have been identified in cervical [11] , lung [12] and renal cell carcinomas [13] . Molecular mechanisms explaining an association between FGD5 amplification and tumour cell proliferation in breast cancer are unknown. Furthermore, an in situ assessment of FGD5 copy number change in breast cancer tissue has, to our knowledge, not previously been performed.
Using a cohort of Norwegian breast cancer patients, the aims of this study were threefold. First, to characterize FGD5 copy number change using fluorescence in situ hybridization (FISH) on formalin-fixed, paraffin-embedded primary tumour tissue and lymph node metastases; second, to assess the association of FGD5 copy number change with proliferation and known prognostic factors such as histologic grade and molecular subtype; and, third, to evaluate the association of FGD5 copy number status with prognosis.
Materials and methods

Study population
A population-based survey for early detection of breast cancer was performed in Nord-Trøndelag County, Norway in 1956-59, and 25,727 women born between 1886 and 1928 were invited. These women were followed for breast cancer occurrence from 1961 to 2008 through the Cancer Registry of Norway. Information on date and cause of death was obtained from the Norwegian cause of death registry. The cohort has previously been described in detail [14] . Briefly, 1379 incident breast cancers occurred from 1961 to 2008, and 909 were reclassified into molecular subtypes. For the present study, FISH was carried out on cases diagnosed after 1985 (n = 453). Of these, five were excluded due to missing or insufficient tumour tissue, and 18 were excluded due to unsuccessful FISH. Thus, 430 cases were suitable for assessment of FGD5 and chromosome 3 centromere (CEP3) copy number in primary tumours.
Of the 430 cases, 146 were lymph node positive at diagnosis, and tissue was available for 115 of these. Two cases were later excluded due to insufficient tumour tissue, and five were excluded due to unsuccessful FISH. Thus, 108 cases were suitable for assessment of FGD5 and CEP3 copy number in lymph node metastases.
Specimen characteristics
All cases were previously classified according to histopathological type and grade [14] , and tissue microarrays (TMA) were constructed using the Tissue Arrayer Minicore Ò 3 with TMA Designer2 software (Alphelys, 78370 Plaisir, France). Three 1-mm tissue cores from the tumour periphery were assembled in recipient blocks. Tumours were reclassified into molecular subtypes using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as surrogates for gene expression analysis ( Supplementary Fig. 1 ). The following antibodies were used: oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki67, and basal markers cytokeratin 5 (CK5) and epidermal growth factor receptor (EGFR) (Supplementary Table 1 ) [14] [15] [16] . HER2 gene status was assessed using CISH.
TMAs were constructed from lymph node metastases, and 4-lm sections were mounted on Superfrost plus glass slides, dried at 37°C overnight and stored in the freezer (-20°C). Slides were stained with HES. For immunohistochemistry, slides were heated at 60°C for 2 h, and pretreatment was carried out in a PT Link, pre-treatment module for tissue specimens (Dako Denmark A/S, 2600 Glostrup, DK) with buffer (Low pH Target Retrieval Solution K8005) at 97°C for 20 min. Immunostaining for Ki67 was carried out in a DakoCytomationAutostainer Plus (Dako) (Supplementary Table 1 ). Dako REAL TM EnVision TM detection system with peroxidase/DAB ? , Rabbit/ Mouse, code K5007, was used for visualization.
FGD5 and CEP3 FISH was done according to the manufacturer's guidelines with some modifications, using Dako Histology Accessory Kit K5799. After de-waxing and rehydration, slides from primary tumours and lymph node metastases were boiled in a microwave oven (10 min) in Pre-treatment Solution, cooled (15 min) and washed in Wash Buffer (3 min 9 2). Protein digestion of tissue samples was performed with Dako Pepsin Solution at 37°C (7 min), and then rinsed in Dako Wash Buffer (3 min 9 2). Dehydration was done in ethanol (70, 85, 100%), for 2 min at each concentration, and slides were air-dried at room temperature (10 min).
FISH custom probeFGD5 (2 lL) (code G110996R-8, Agilent Technologies) and SureFISHChr3 CEP (2 lL) (G101065G-8, Agilent Technologies) were mixed in IQFISH Fast Hybridization buffer (18lL) (code G9415A, Agilent Technologies) and applied to TMA slides. Coverslips were applied and sealed with Dako Coverslip Sealant. Denaturation was performed at 80°C (10 min), and hybridization was done at 45°C for 120 min using Dako Hybridizer. Post-hybridization wash was done with Dako Stringent Wash Buffer at 62.5°C (10 min), and with Dako Wash Buffer (3 min 9 2). Slides were air-dried at 37°C (30 min), mounted with Dako Fluorescence Mounting Medium, and coverslipped.
The REMARK criteria for reporting tumour marker studies were followed [17] .
Scoring and reporting
FGD5 and CEP3 copy number were assessed in a fluorescence microscope (Nikon Eclipse 90i). For each case, all available TMA spots were examined, and the proportion of tumour cells with [2 FGD5 copies/cell was recorded. FGD5 and CEP3 copy number in 20 non-overlapping, well-preserved tumour cells was then recorded, and, if present, tumour cells with FGD5 copy number increase ([2) were selected. The observer was blinded for other tumour data. For each case, a gene-to-chromosome ratio was estimated, dividing the sum of FGD5 copies by the sum of CEP3 copies in 20 tumour cells.
To assess the impact of FGD5/CEP3 ratio, cases were divided into three categories: (1a) Cases with B2 FGD5 copies/nucleus in all tumour cells; (1b) Cases with [2 FGD5 copies/nucleus in some tumour cells, and FGD5/ CEP3 ratio \2; and (1c) Cases with [2 FGD5 copies/ nucleus in some tumour cells, and FGD5/CEP3 ratio C2.
To assess the impact of FGD5 copy number change regardless of FGD5/CEP3 ratio, mean FGD5 copy number was estimated for each case. Cases were then divided into three categories: (2a) Cases with mean FGD5 copies/nucleus B2; (2b) cases with mean FGD5 copies/nucleus [ 2 \ 4; and (2c) Cases with mean FGD5 copies/nucleus C4.
Finally, tumours were defined as amplified when FGD5/ CEP3 C 2 and/or mean FGD5 C 4 (Category 3b), and as non-amplified when FGD5/CEP3 \ 2 and mean FGD5 \ 4 (Category 3a).
Statistical analyses
We used Pearson's Chi square test to compare proportions of patient and tumour characteristics across categories of FGD5 copy number status in primary tumours and lymph node metastases. For each category of FGD5 status in primary tumours, cumulative incidence of death from breast cancer was estimated, considering death from other causes a competing event. Gray's test was used to test for equality between cumulative incidence curves. We used Cox proportional hazards models to estimate hazard ratios (HRs) of death from breast cancer (with 95% confidence intervals (CIs)) according to FGD5 status in primary tumours, censoring at time of death from other causes. Category 1a was used as the reference in the assessment of prognosis according to FGD5/CEP3 ratio, category 2a in analyses according to mean FGD5 copy number/nucleus and category 3a in assessment of prognosis according to FGD5 amplification status. Adjustments were made for other prognostic factors at baseline, including age (B49, 50-59, 60-64, 65-69, 70-74, C75 years), stage (I, II, III, IV), histological grade, Ki67 (\/C15%) and molecular subtype. Adjustments were made for each variable separately, and for all variables combined. No clear violations of proportionality were observed in log-minus-log plots. Stata version 13.1 (Stata Corp., College Station, TX, USA) was used for the statistical analyses.
Results
Mean age at diagnosis was 76.0 years, and mean follow-up after diagnosis was 8.0 years (Table 1) .
FGD5 in the primary tumours
FISH analysis of breast cancer tumours revealed three distinct patterns, denoted a, b and c ( Fig. 1 ): Cases with a maximum of 2 FGD5 and CEP3 copies in all nuclei (a); cases with copy number [2 for both FGD5 and CEP3 (b); and cases with copy number [2 for FGD5, but not for CEP3 (c). We identified tumour cells with [2 copies of FGD5 in 308 cases (72%, Table 1 ). A total of 26 cases (6%) had FGD5/CEP3 ratio C2, 229 cases (53%) had a mean FGD5 copy number [ 2 \ 4, and 32 cases (7%) had a mean copy number C 4. By defining FGD5 amplification as FGD5/CEP3 ratio C 2 and/or mean copy number C 4, 41/430 cases (9.5%) were found to be amplified.
The distribution of cells with increased FGD5 copy number was focal in many cases, either as dispersed single cells or as small clusters of cells. Among all cases with FGD5 copy number increase, the median proportion of tumour cells with [2 FGD5 copies/cell was 10% (IQR 4-20%). Among amplified cases (FGD5/CEP3 ratio C2 and/or mean FGD5 C4), the median proportion was higher (20%, IQR 15-40).
FGD5 copy number increase was identified within all molecular subtypes, and amplified cases were found in all molecular subtypes except the five negative phenotype (Table 1) .
FGD5 in lymph node metastases
FISH analysis showed that the three phenotypic patterns (a, b, c) described above were also present in the lymph node metastases. 
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The distribution of cells with FGD5 copy number increase was often focal and dispersed. Among all cases with FGD5 copy number change in the lymph nodes, the median proportion of tumour cells with[2 copies of FGD5 was 9% (IQR 4-20). Among amplified cases, the median proportion was higher (25%, IQR 20-30).
FGD5, proliferation and histological grade
Mitotic count was higher in amplified, compared to nonamplified tumours (29 vs. 21% in highest quartile, Max. maximum a Cells with [2 FGD5 copies present, and FGD5/CEP3 ratio \2 p \ 0.001, Table 1 ). Ki67 levels were also higher in amplified tumours (54 vs. 36% had Ki67 C 15%, p = 0.026). Cases with FGD5 amplification had a higher proportion of grade 3 tumours, compared to non-amplified cases (59 vs. 28%, p \ 0.001).
We found no clear association between FGD5 copy number increase and Ki67 levels in lymph node metastases (Supplementary Table 2 ).
FGD5 and prognosis
Prognosis according to FGD5/CEP3 ratio
For cases without FGD5 copy number increase (Category 1a), cumulative risk of death from breast cancer after 10 years of follow-up was 23.7% (95% CI 16.9-32.7) ( Table 3 ; Fig. 2 ). For Category 1b and 1c, the corresponding cumulative risks of death were higher (30.5% (95% CI 25.4-36.5) and 47.0% (95% CI 29.9-67.8), respectively).
Comparing rates of death between categories, we found higher rates among patients in Category 1b and 1c, compared to Category 1a (age-adjusted HRs of 1.4 (95% CI 0.9-2.1) and 2.6 (95% CI 1.3-4.9), respectively). Adjustments for grade, stage, Ki67 and molecular subtypes gave similar results, regardless of whether adjustments were made for each variable separately, or for all variables combined.
Prognosis according to mean FGD5 copy number/tumour cell
Cumulative risk of death from breast cancer increased with increasing mean FGD5 copies/nucleus (Table 3 ; Fig. 2 ). For cases with mean FGD5/cell B 2 (Category 2a), cumulative risk after 10 years of follow-up was 22.6% (95% CI 16.8-29.9). For cases with mean FGD5/ cell [ 2 \4 (Category 2b), the corresponding risk was 32.1% (95% CI 26.3-38.8), and, for patients with mean FGD5/tumour cell C4 (Category 2c), risk of death was 49.6% (95% CI 33.3-68.5).
Comparing rates of death, we found higher rates among patients in Category 2b and 2c, compared to Category 2a (age-adjusted HRs of 1.6 (95% CI 1.1-2.4) and 2.6 (95% CI 1.4-4.6), respectively). Adjustments for grade, stage, Ki67 and molecular subtype gave similar results for category 2b, both after adjustment for each variable separately and for all variables combined. For category 2c, the HR after adjustment for all factors combined was attenuated to 1.6 (95% CI 0.8-3.0).
Prognosis according to FGD5 amplification status
For non-amplified cases, cumulative risk of death from breast cancer after 10 years of follow-up was 27.7% (95% CI 23.4-32.6) ( Table 4 ; Fig. 2 ). For amplified cases (FGD5/CEP3 ratio C2 and/or mean FGD5 C 4), the corresponding cumulative risk of death was higher (48.1% (95% CI 33.8-64.7)). We found higher rates of death from breast cancer among amplified cases, compared to non-amplified cases (age-adjusted HR 2.0 (95% CI 1.2-3.2). After adjustments for age, grade, stage, Ki67 and molecular subtype, the HR was attenuated to 1.4 (95% CI 0.8-2.3).
FGD5 and prognosis within molecular subtypes of breast cancer
For Luminal A cases, cumulative risk of death 10 years after diagnosis was higher for cases with FGD5 copy number increase, compared to cases without (Supplementary Table 3 ; Supplementary Fig. 2 ). For category 1a, cumulative risk of death 10 years after diagnosis was 20% (95% CI 12.1-32.1), and, for category 1c, the corresponding risk was 27.7% (95% CI 9.9-63.7). Category 1b had a better prognosis than category 1a 5 years after diagnosis. For category 2a, cumulative risk after 10 years was 16.1% (95% CI 10.0-25.4), and, for category 2c, the corresponding risk was 34.8% (95% CI 16.1-64.9).
FGD5-amplified Luminal A cases had a higher risk of death from breast cancer than non-amplified cases. The cumulative risks of death estimates 10 years after diagnosis were 34.3% (95% CI 17.0-61.2) and 21% (95% CI 15.9-27.4), respectively (Supplementary Table 4) .
Comparing rates of death between categories, we found a poorer prognosis with increasing FGD5/CEP3 ratio and with increasing mean FGD5, and for amplified cases compared to non-amplified cases (Supplementary Tables 3  and 4 ). For the remaining subtypes, statistical power was considered too limited for separate survival analyses.
Discussion
We identified FGD5 copy number increase in primary tumours and lymph node metastases in a large proportion of breast cancer patients. FGD5 amplification in the primary tumour was associated with higher proliferation and poorer survival.
Using FGD5/CEP3 ratio C2 and/or FGD5 copy number C4 as a definition of gene amplification, 41 cases (9.5%) were amplified. We are not aware of other studies where FGD5 gene amplification status in breast cancer has been assessed by FISH. However, in the TCGA dataset, 15% of cases were found to be FGD5-amplified by copy number analysis, whereas in the METABRIC dataset, 3% were amplified [5] .
In accordance with Gatza et al., we found that FGD5 amplification was associated with higher proliferation and poorer prognosis. In our study, FGD5-amplified cases had a higher mitotic count and higher Ki67 levels than nonamplified cases. The prognosis of patients with FGD5 copy number increase was poorer, both when analyses were based on FGD5/CEP3 ratio and on mean FGD5 copy number. Comparing rates of death between amplified and non-amplified cases, we found that associations were attenuated and less clear after adjustments for grade, Ki67 levels, stage and molecular subtype. The question is whether adjustments for these factors are justified. If FGD5 amplification is a driver of proliferation, as suggested by Gatza et al. [5] , then consequences of FGD5 amplification could, at least in part, be mediated through grade, stage and Ki67 levels. Although valuable from a prognostication perspective, adjustments for these factors could mask the overall role of FGD5 as a driver of breast cancer progression [18] .
In the study by Gatza et al., FGD5 was uniquely amplified in highly proliferative luminal tumours. Subtyping was based on gene expression analysis, and luminal tumours were defined as all tumours that were not Basal [5, 19] . We categorized tumours into six different subtypes based on IHC and ISH as surrogates for gene expression analysis, and found amplifications in all subtypes, except the five negative phenotype. Even though studies have shown good correlation between subtyping by gene expression and surrogate markers, classification by these two methods is not identical [20] [21] [22] . Furthermore, focal FGD5 copy number increase may be easier to identify with an in situ technique, such as FISH, than with copy number analysis. This could explain why we, contrary to Gatza, identified FGD5 copy number increase in all molecular subtypes.
We found some Luminal A tumours with FGD5 copy number increase. According to our subtyping algorithm, Luminal A tumours have Ki67 levels \15%, and are thus not highly proliferative. In this cohort, we have found that Ki67 levels in TMAs are generally lower than in the corresponding whole sections (unpublished data), a finding that is in accordance with others [23] . It is therefore possible that some of our Luminal A cases are misclassified Luminal B tumours. Furthermore, 5/18 (28%) of the FGD5 amplified Luminal A tumours were histological grade 3. According to the recent St. Gallen Expert Consensus, histological grade 3 Luminal A tumours could represent misclassified Luminal B tumours [2] .
Using FISH, we were able to study FGD5 gene-and CEP3 copy number status while observing the morphology of breast cancer tumours. Thus, only invasive epithelial tumour cells were assessed, and the distribution and proportion of amplified cells could be evaluated. Amplification has been defined as a copy number increase in a segment of the genome [24] ; however, there is no established gold standard as to how gene amplification should be defined. According to current HER2 treatment guidelines [25] , both HER2/centromere 17 (CEP17) ratio and HER2 copy number (regardless of ratio) are taken into account [26, 27] . FGD5 is a new marker with no available guidelines for assessment. Using a centromere probe in addition to the gene probe, we could assess the prognostic value of both FGD5/CEP3 ratio and of mean FGD5 copy number. When present, cells with FGD5 copy number increase were selected for assessment, even when such changes were seen only focally. One could argue that the overall mean copy numbers of FGD5 and CEP3 would be a better way to report each tumour. However, this approach could mask the potential prognostic impact of the focal changes identified in this study.
FGD5 amplification status in primary tumours and lymph node metastases was assessed in TMAs, comprising three 1-mm tissue cores from each case. When present, amplifications were only identified in a proportion of tumour cells. Previous studies have shown good correlation between TMA and whole sections for other markers [28] [29] [30] , but it is likely that intratumoural heterogeneity may have led to an underestimation of cases with gene amplification in the present study. The presence of FGD5-amplified cells in the lymph nodes of some patients without findings in the primary tumour support this hypothesis. Thus, the observed associations of FGD5 amplification with tumour characteristics and prognosis may underestimate the true effect of FGD5 copy number increase. Still, a high number of comparisons were made, and, with a limited number of amplified cases, the CIs were relatively wide.
Molecular mechanisms explaining the association between FGD5 amplification and proliferation and prognosis are unknown. However, FGD5 is expressed in hematopoietic stem cells [31] and in vascular endothelial cells, and it has been found to regulate the proangiogenic effect of vascular endothelial growth factor (VEGF), including network formation, cell-matrix interaction, endothelial cell permeability, movement, proliferation and adhesion [32, 33] .
We were able to reproduce the main findings from Gatza's study in our cohort of breast cancer patients, with a mean age at diagnosis of 76 years. It has been suggested that proliferation is a stronger prognostic factor in younger breast cancer patients [34] . Therefore, amplification of FGD5, a gene associated with proliferation, could be of greater relevance in prognostication of younger breast cancer patients. It is necessary to validate our findings in a cohort of younger breast cancer patients.
In conclusion, FGD5 has been identified as an essential gene in breast cancer proliferation, making it valuable as a prognostic marker, and a potential target for treatment. Using FISH in a large, well-described cohort of breast cancer patients, we have demonstrated that FGD5 amplification is associated with higher proliferation and a poorer prognosis.
